针对多发性骨髓瘤患者的B细胞成熟抗原:当前前景观
Trilok Shrivastava1, Frits Van Rhee1, Samer Al Hadidi1
1Myeloma Center, Winthrop P. Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
OncoTargets and therapy
|June 26, 2023
概括
针对B细胞成熟抗原 (BCMA) 的新疗法为复发性/耐药性多发性骨髓瘤提供了有前途的选择. 本综述涵盖双特异性抗体,抗体药物合物和CAR T细胞疗法,重点关注疗效和不良事件.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 复发性/耐药性多发性骨髓瘤带来了重大的治疗挑战.
- 最近的治疗进展包括针对B细胞成熟抗原 (BCMA) 的新方法.
研究的目的:
- 审查当前针对多发性骨髓瘤的B细胞成熟抗原 (BCMA) 向疗法.
- 为了解BCMA向治疗的临床疗效和不良事件提供见解.
- 讨论未来的BCMA向疗法的发展.
主要方法:
- 对现有的BCMA向疗法的文献综述.
- 对双特异性抗体 (BsAbs),抗体药物联合体 (ADC) 和仿制抗原受体 (CAR) T 细胞疗法的临床疗效数据的分析.
- 与药物相关的常见不良事件的总结.
主要成果:
- BCMA是表达在恶性等离子体细胞上的关键标.
- 双特异性抗体 (BsAbs),抗体药物合物 (ADC) 和模拟抗原受体 (CAR) T细胞疗法代表了主要的BCMA向方法.
- 这些疗法显示出显著的临床活性,但与特定的不良事件有关.
结论:
- 针对BCMA的向疗法已经彻底改变了多发性骨髓瘤治疗.
- 了解有效性和安全性概况对于最佳的患者管理至关重要.
- 目前正在进行的研究有望在BCMA导向治疗方面取得进一步的进展.
更多相关视频
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
13.1K
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
6.9K
相关概念视频
B Cell Activation and Differentiation
1.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
1.8K
Hybridoma Technology
15.0K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.0K
T Cell Activation and Clonal Selection
837
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
837
